EUCTR2013-001037-40-DE进行中（未招募）1 期
A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29 - SCIENS
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- InflaRx GmbH
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients = 18 years old
- •2. Written informed consent
- •3. Occurrence of at least two criteria of a systemic inflammatory response syndrome (SIRS)
- •4. Suspected or confirmed abdominal or pulmonary infection
- •5. Broad spectrum i.v. antimicrobial therapy to treat abdominal or pulmonary infection which is also effective against N. meningitidis
- •6. At least one organ dysfunction due to sepsis
- •7. A reasonable likelihood that administration of study drug can be started within 3.5 hours after start of screening process.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 37
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •1. Sepsis of other primary cause than pulmonary or abdominal source
- •2. Weight > 130 kg
- •3. Any other disease and condition that is likely to interfere with evaluation of study product, outcome assessment or satisfactory conduct of the study
- •a. Infection where guidelines recommend a longer duration (i.e. more than 2 weeks) of antimicrobial therapy
- •b. meningitis
- •c. Life expectancy less than 6 months due to concomitant diseases
- •d. Significant hepatic impairment
- •e. Active hepatitis
- •f. Severe congestive heart failure
- •g. Severe central neurological impairment
- •h. Cardiopulmonary resuscitation in the 4 weeks prior to screening
- •4. Patients receiving the following concomitant medication within 14 days prior to screening:
- •a. Calcineurin inhibitors
- •b. Proliferation inhibitors
- •c. Anti-metabolites
- •d. High dose corticosteroids
- •5. Patients receiving high dose immunoglobulins (e.g., IVIG, Pentaglobin®) within 3 months prior to screening
- •6. Neutrocytopenia
- •6. General criteria
- •a. Pregnant or breast-feeding women
- •b. Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate contraceptive measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial
- •c. Participation in any interventional clinical trial within the last 3 months
- •d. Prior participation in this clinical trial
- •e. Patient is chronically bed-bound prior to the onset of sepsis
- •f. Known intravenous drug abuse
- •f. Employee at the study site, or spouse/partner or relative of any study staff
- •h. No commitment to full aggressive life support
研究者
相似试验
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing complex cardiac surgery (CARDIAC)Prevention of organ dysfunction induced by inflammatory response after complex cardiac surgeryMedDRA version: 20.0Level: PTClassification code 10063101Term: Post procedural inflammationSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 20.0Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 100000004867EUCTR2015-003036-12-DEInflaRx GmbH
进行中（未招募）
1 期
A Clinical Study to evaluate Ladarixin as an additional therapy to improve glycemic control in overweight insulin resistance patients with type 1 diabetes.EUCTR2022-000743-68-ITDOMPé FARMACEUTICI S.P.A.86
进行中（未招募）
不适用
A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI) - N/ARecurrence of Clostridium difficile Infection (CDI)MedDRA version: 12.0Level: LLTClassification code 10006834Term: C.difficile diarrheaMedDRA version: 12.0Level: LLTClassification code 10006835Term: C.difficile diarrhoeaMedDRA version: 12.0Level: LLTClassification code 10012734Term: Diarrhea, Clostridium difficileMedDRA version: 12.0Level: LLTClassification code 10012748Term: Diarrhoea, Clostridium difficileMedDRA version: 12.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileMedDRA version: 12.0Level: LLTClassification code 10054236Term: Clostridium difficile infectionEUCTR2008-004907-69-GBSanofi Pasteur Inc.612
进行中（未招募）
1 期
An European study to assess safety and efficacy of a new drug in patients with worsening chronic heart failure.Patient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 19.1Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2015-005607-92-HUQuantum Genomics75
进行中（未招募）
1 期
An European study to assass safety and efficacy of a new drug in patients with worsening chronic heart failure.Patient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000011680EUCTR2015-005607-92-CZQuantum Genomics75